Stopping Anti-TNF in CD Remitters: Cons

Area of Science:

• Gastroenterology and Immunology
• Inflammatory Bowel Disease Research

Background:

• Crohn's disease presents a lifelong burden due to its progressive nature.
• Anti-tumor necrosis factor (anti-TNF) therapy is a cornerstone for refractory Crohn's disease patients.
• Discontinuation of anti-TNF agents is infrequently practiced, with limited data on relapse predictors.

Purpose of the Study:

• To review the current understanding of anti-TNF discontinuation strategies in Crohn's disease.
• To highlight the observed relapse rates and potential predictive factors following anti-TNF cessation.
• To inform clinical decision-making regarding the risks and benefits of stopping anti-TNF therapy.

Main Methods:

• Review of observational studies on anti-TNF discontinuation in Crohn's disease patients.
• Analysis of reported relapse rates post-treatment cessation.
• Identification and discussion of suggested, yet unconfirmed, relapse predictors.

Main Results:

• Approximately 50% of Crohn's disease patients experience relapse within one year of stopping anti-TNF treatment.
• Several factors are proposed as relapse predictors, but no consensus exists.
• While re-treatment with the same anti-TNF agent is often effective, some patients face disease progression and surgical needs.

Conclusions:

• Discontinuing anti-TNF therapy in Crohn's disease carries a significant risk of relapse.
• Predicting relapse remains challenging due to a lack of consensus on key factors.
• Stopping anti-TNF treatment should be approached with caution and thorough patient discussion, even in long-term remission, to mitigate risks of disease progression and surgery.